Acute Care Volume 23, Issue 25

Medication Safety Alert! December 13, 2018

In this week's issue:

Featured article

In the latest issue of ISMP’s QuarterWatch™, we examine the adverse drug events reported to the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) for 97 new drugs and biological products approved between 2015 and 2017, including:

  • evolocumab (REPATHA) and alirocumab (PRALUENT), a new generation of cholesterol-lowering biological products that reduce low-density lipoprotein (LDL)

  • secukinumab (COSENTYX) and ixekizumab (TALTZ), two of the newest treatments for plaque psoriasis and psoriatic arthritis

  • dupilumab (DUPIXENT), a new immunosuppressant to treat...

Access this Newsletter

Purchasing Options

Purchase access to this individual issue

Purchase a year's access to this bi-weekly publication (25 issues)